Available in Colombia, Brazil
This is a Phase III, two-arm, randomized, double-blind, global, multicenter study
assessing the efficacy and safety of rilvegostomig compared to pembrolizumab as a 1L
treatment for patients with mNSCLC whose tumors express PD-L1.
830Patients around the world